LIMNHealthcare · Biotechnology

LIMN Stock Forecast: Liminatus Pharma, Inc. Price Predictions for 2026-2027

Last close, 15 Sept 2026

$3.51

−0.28% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 11 of 100 as at 14 Sept 2026 — in the weakest quartile.

Market cap

$4.7M

Ticker Nerd rank

11 / 100

Median analyst target

—

Analysts covering

—

Revenue$0.0

Operating income−$1.4M

Net income−$1.4M

Free cash flow−$970K

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−3.0%

−49.9%

YTD

−88.5%

−96.2%

From 52W high

−96.6%

From 52W low

+1.2%

$103

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

LIMN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Liminatus Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026

11 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Volatility

Issuance

Revisions

Value

Momentum

Quality

Growth

Size (96): Smaller than most of the companies we track.

Growth (9): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LIMN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LIMN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LIMN appears on the weeks it earns a place.

Performance

LIMN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 15 Sept 2026, Liminatus Pharma, Inc. returned −96.2% against +16.4% for the S&P 500, dividends included.

LIMN vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LIMN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Liminatus Pharma, Inc. (LIMN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −8.2×
Price / sales: —
Price / book: 12.9×
EV / EBITDA: −0.8×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: 104.0%
Return on assets: −95.7%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Liminatus Pharma, Inc. (LIMN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Liminatus Pharma, Inc. has a market value of $4.7M and an enterprise value of $3.1M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$12.5M.
Free cash flow in the twelve months to 30 June 2026: −$4.0M.
Shares outstanding: 56.0M.
Trailing P/E: −8.2×.
Liminatus Pharma, Inc. employs 1 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

LIMN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
LIMNLiminatus Pharma, Inc.	$4.7M	11
VIVSVivoSim Labs, Inc.	$4.7M	33
DRMADermata Therapeutics, Inc.	$4.6M	27
HCWBHCW Biologics Inc.	$4.9M	63
JUNSJupiter Neurosciences, Inc.	$4.5M	10
LABTLakewood-Amedex Biotherapeutics, Inc.	$5.0M	21
MLECMoolec Science SA	$5.2M	3

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Liminatus Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LIMN news & analysis

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

GlobeNewsWire · 24 Aug 2026positive

Liminatus Pharma announced it has engaged Synex Consulting Ltd. as a contract research organization to support the Phase 1/2a clinical development of its CD19xCD22 bivalent CAR-T therapy. The announcement was made via GlobeNewsWire on Aug. 24, 2026.

Why it matters — LIMN watchers would care because engaging a CRO signals progress toward advancing the company's lead CAR-T candidate into clinical trials.

Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock

GlobeNewsWire · 18 Aug 2026neutral

Liminatus Pharma, Inc. announced that its board of directors adopted resolutions approving a 1-for-50 reverse stock split of its common stock. The split was approved by stockholders at the Company's 2026 Annual Meeting of Stockholders held on August 3, 2026.

Why it matters — A 1-for-50 reverse stock split will consolidate the number of outstanding shares and correspondingly adjust the per-share price of LIMN common stock, a significant corporate action for shareholders to track.

Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement

GlobeNewsWire · 13 Aug 2026neutral

Liminatus Pharma announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026, and that the Nasdaq Hearings Panel granted the Company additional time to demonstrate compliance with Nasdaq's minimum bid price requirement.

Why it matters — This update is relevant to LIMN watchers because it addresses the Company's continued Nasdaq listing status and its bid price compliance timeline.

FAQ

Frequently asked questions about LIMN stock

How does Ticker Nerd's model rank LIMN?

As at 14 Sept 2026, Liminatus Pharma, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).

What is the LIMN stock forecast for 2030?

No analyst covering Liminatus Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LIMN are extrapolating price history, which says nothing about the business.

How has LIMN stock performed over the past year?

Liminatus Pharma, Inc. returned -96.2% over the 12 months to 15 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Liminatus Pharma, Inc. do?

Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies for cancer.

What is the latest news on LIMN?

The most recent item we track (GlobeNewsWire, 24 Aug 2026): "Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy". Liminatus Pharma announced it has engaged Synex Consulting Ltd. as a contract research organization to support the Phase 1/2a clinical development of its CD19xCD22 bivalent CAR-T therapy. The announcement was made via GlobeNewsWire on Aug. 24, 2026.

Company

About Liminatus Pharma, Inc.

Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies for cancer. The company’s current work centers on immune-modulating treatments designed to address solid tumors, with a particular emphasis on CD47-blockade technology and its candidate IBA101, a humanized anti-CD47 monoclonal antibody. Liminatus Pharma is also associated with broader oncology research efforts that explore next-generation immune-based approaches and CAR-T platforms for difficult-to-treat cancers. Its business is concentrated in the biotechnology and healthcare sectors, where it contributes to the development of targeted cancer therapies intended to expand treatment options in oncology. Founded in 2018 and headquartered in California, Liminatus Pharma remains focused on advancing clinical research and therapeutic development for patients with unmet needs in cancer care.

CEO Mr. Chris Kim J.D., L.L.M. · 1 employees · United States · https://liminatuspharma.com